M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Phase 2

Withdrawn

Conditions: Metastatic Olfactory Neuroblastoma
Recurrent Olfactory Neuroblastoma

Interventions: Drug: Rivoceranib

First Posted Date: 2024-03-13

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT06308575

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Phase 1

Recruiting

Conditions: Leiomyosarcoma
Soft-tissue Sarcomas

Interventions: Drug: Gemcitabine
Drug: Nab-Sirolimus

First Posted Date: 2024-03-13

Last Posted Date: 2025-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT06308419

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Philadelphia Chromosome-Positive
Acute Lymphoblastic Leukemia

Interventions: Drug: Blinatumomab
Drug: Asciminib

First Posted Date: 2024-03-13

Last Posted Date: 2025-03-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06308588

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Phase 2

Withdrawn

Conditions: Allogeneic Stem Cell Transplantation

Interventions: Drug: ASTX727
Drug: Donor Lymphocyte Infusion

First Posted Date: 2024-03-07

Last Posted Date: 2025-04-09

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT06297629

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect

Recruiting

Conditions: Radiation

Interventions: Other: MDASI-HN
Other: EORTC QLQ-C30
Other: EORTC HN35

First Posted Date: 2024-03-06

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 300

Registration Number: NCT06295783

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

Phase 1

Recruiting

Conditions: B-cell Acute Lymphocytic Leukemia
Relapsed/Refractory

Interventions: Drug: Blinatumomab
Drug: Inotuzumab Ozogamicin
Drug: Hyper-CVAD
Drug: Mini-hyper-CVD

First Posted Date: 2024-03-01

Last Posted Date: 2025-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06287229

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain

Phase 1

Recruiting

Conditions: Hypophysectomy

Interventions: Device: Stereotactic Radiosurgery

First Posted Date: 2024-03-01

Last Posted Date: 2025-01-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06287515

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Revumenib

First Posted Date: 2024-02-29

Last Posted Date: 2025-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT06284486

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Phase 1

Withdrawn

Conditions: Myeloproliferative Neoplasm
Myelodysplastic Neoplasm
Pathway Mutant Myelodysplastic Syndromes

Interventions: Drug: ASTX029
Drug: ASTX727

First Posted Date: 2024-02-29

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT06284460

Locations: 🇺🇸
MD Anderson Cancer Cente, Houston, Texas, United States

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: HC-7366

First Posted Date: 2024-02-29

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT06285890

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy